Many clinical and pathological discussions have been focused on the difficulty of differential diagnosis between corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) in recent years. This study was conducted to evaluate the usefulness of tau proteins in cerebrospinal fluid (CSF) for the differentiation of these two diseases. Subjects consisted of 10 patients with CBD (four males and six females with a mean age of 67.9 ± 5.8 years), 12 patients with PSP (eight males and four females with a mean age of 62.6 ± 5.8 years) and 36 control subjects (CTL) (16 males and 20 females with a mean age of 65.8 ± 9.9 years). The CBD group included patients with probable CBD, while all the patients in the PSP group satisfied the diagnostic criteria developed by the National Institute of Neurological Disorders and Stroke and Society for PSP (NINDS-SPSP). CSF tau proteins were measured with the sandwich ELISA method (Innogenetics, Belgium). The CSF tau protein level was 320.1 ± 86.5 pg/ml in the CBD group, 151.5 ± 52.7 pg/ml in the PSP group and 128.7 ± 91.7 pg/ml in the CTL group. Significant differences were noted in tau protein levels between the CBD group and both the PSP group (P < 0.001) and the CTL group (P < 0.005). We suggested that the measurement of CSF tau proteins may be useful for the differentiation between CBD and PSP.
- Corticobasal degeneration
- Diagnostic marker
- Progressive supranuclear palsy
- Tau proteins in cerebrospinal fluid
ASJC Scopus subject areas